ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Anti-arthritic and anti-inflammatory effects of BMZD-2CPE in a CFA and carrageenan-induced animal model.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The goal of the study was to evaluate the anti-inflammatory and immunomodulatory effects of benzimidazole derivative-2-((1H-benzo[d] imidazole-2-yl)thio)-1-(3-(3-chlorophenyl)-5-phenyl-1 H-pyrazol-1-yl) ethanone (BMZD-2CPE) in CFA-induced arthritic rat model. The doses of the BMZD-2CPE (benzimidazole derivative) used were 25, 50, and 75 mg/kg, respectively. Treatment with BMZD-2CPE and piroxicam was started on the 7th day of arthritic induction and continued for 20 days. All animals were sacrificed on the 27th day. A digital water plethysmometer was used to measure paw edema. An arthritic scoring index was used to determine the presence of arthritis. Biochemical parameters and blood analysis were determined. q-PCR was used to assess the mRNA expression of pro-inflammatory cytokines such as TNF-α and IL-6. PGE2 levels were determined using ELISA. The anti-inflammatory properties of BMZD-2CPE were evaluated using an acute inflammatory carrageenan-induced paw edema model. BMZD-2CPE reduced paw edema and slowed the progression of arthritic disease. After receiving BMZD-2CPE treatment, all histopathological parameters were seen to be considerably decreased. mRNA expression levels of pro-inflammatory cytokines such as TNF-α and IL-6 were markedly decreased in treatment groups. BMZD-2CPE also downregulated PGE2 levels in treatment groups. All results were comparable to piroxicam. Hemoglobin (Hb) and red blood cell (RBC) levels were restored in the treated groups. Furthermore, the levels of white blood cells and platelets in the treated groups were significantly reduced. Creatinine, urea, alanine transaminase, and aspartate aminotransferase levels were found to be non-significantly different indicating safety of the compound. BMZD-2CPE in various doses (more potentially in higher dose) showed anti-inflammatory and immunomodulatory properties.
Indexed as
Identifiers
41026177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.